ImCheck Therapeutics
ImCheck Therapeutics is a clinical-stage immuno-oncology company developing novel antibody therapies.
About
ImCheck Therapeutics is a clinical-stage biotechnology company focused on developing a new generation of immuno-oncology drugs. Their approach targets novel immune checkpoints to modulate the tumor microenvironment and enhance anti-tumor immunity. The company's lead product candidate, IMC-001, is a first-in-class antibody targeting the TIGIT receptor. Teams look it up for Biotech, MedTech, HealthTech.
Frequently asked
What does ImCheck Therapeutics do?
ImCheck Therapeutics is a Biotech company that offers Biotech. Teams look it up for MedTech, HealthTech, Drug Discovery. It is based in Marseille, France and was founded in 2015. Public records show about 47 people and $164M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has ImCheck Therapeutics raised?
ImCheck Therapeutics has raised a total of $164M in funding.
Where is ImCheck Therapeutics headquartered?
ImCheck Therapeutics is headquartered in Marseille, France.
When was ImCheck Therapeutics founded?
ImCheck Therapeutics was founded in 2015.
What industry does ImCheck Therapeutics operate in?
ImCheck Therapeutics operates in Biotech, MedTech, HealthTech, Drug Discovery, Clinical Trials.
How many employees does ImCheck Therapeutics have?
ImCheck Therapeutics has approximately 47 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.